These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37146743)

  • 21. [Fluorescence Angiography-assisted Management of Recurrences in Aggressive Posterior Retinopathy of Prematurity (APROP) after Intravitreal Monotherapy with 0.312 mg Bevacizumab].
    Andrassi-Darida M; Mais C; Stieger K; Lorenz B
    Klin Monbl Augenheilkd; 2020 Dec; 237(12):1468-1476. PubMed ID: 31770787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.
    Chen TA; Shields RA; Bodnar ZH; Callaway NF; Schachar IH; Moshfeghi DM
    Am J Ophthalmol; 2019 Feb; 198():63-69. PubMed ID: 30312578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
    Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
    Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
    Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
    Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between refractive outcomes and quantitative retinal vascularization and severity of plus disease in eyes treated with intravitreal bevacizumab.
    Bayramoglu SE; Sayin N
    Indian J Ophthalmol; 2022 Oct; 70(10):3584-3590. PubMed ID: 36190051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal Development of Refractive Error in Children Treated With Intravitreal Bevacizumab or Laser for Retinopathy of Prematurity.
    Simmons M; Wang J; Leffler JN; Li S; Morale SE; de la Cruz A; Birch EE
    Transl Vis Sci Technol; 2021 Apr; 10(4):14. PubMed ID: 34003992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term retinal vasculature abnormalities following intravitreal bevacizumab for retinopathy of prematurity.
    Sternfeld A; Rahmani S; Rossen JL; Zhang DL; Li YD; Quan VL; Huang R; Yoon HH
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1915-1921. PubMed ID: 34851464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
    Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
    Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computed Analysis of Retinal Vascular Growth After Bevacizumab Treatment of Retinopathy of Prematurity Until Age 3 Years.
    Hammer JD; Nguyen H; Palmer J; Furtney S; Agarwal-Sinha S
    Clin Ther; 2023 Jan; 45(1):4-16. PubMed ID: 36581528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity.
    Eftekhari Milani A; Hassanpoor N; Mousavi Mirkala M; Taheri A; Golizade A; Niyousha MR
    Int Ophthalmol; 2020 Feb; 40(2):477-482. PubMed ID: 31712928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab.
    Barry GP; Tauber KA; Fisher M; Greenberg S; Zobal-Ratner J; Binenbaum G
    J AAPOS; 2019 Oct; 23(5):260.e1-260.e4. PubMed ID: 31513902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing reactivation and retreatment for three doses of bevacizumab in type 1 retinopathy of prematurity.
    Chopra J; Haider KM; Boente CS
    J AAPOS; 2024 Apr; 28(2):103866. PubMed ID: 38458598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
    Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
    Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive Outcomes Following Intravitreal Bevacizumab for Retinopathy of Prematurity: 4- to 6-Year Outcomes in a Prospective Cohort.
    Chou HD; Shih CP; Huang YS; Liu L; Lai CC; Chen KJ; Hwang YS; Wu WC
    Am J Ophthalmol; 2022 Feb; 234():59-70. PubMed ID: 34283975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression.
    Vural A; Ekinci DY; Onur IU; Hergünsel GO; Yiğit FU
    Int Ophthalmol; 2019 Oct; 39(10):2267-2274. PubMed ID: 30604251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy.
    Kuo HK; Sun IT; Chung MY; Chen YH
    Ophthalmologica; 2015; 234(4):211-7. PubMed ID: 26393895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.
    Kıran Yenice E; Petriçli İS; Kara C
    Int Ophthalmol; 2023 Jul; 43(7):2197-2202. PubMed ID: 36522564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.
    Nazari H; Modarres M; Parvaresh MM; Ghasemi Falavarjani K
    Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1713-8. PubMed ID: 20582706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiographic Review of Choroidal Involution in Eyes with Retinopathy of Prematurity Treated with Bevacizumab.
    Islam Y; Andersen L; Agarwal-Sinha S
    Ophthalmic Res; 2022; 65(2):229-236. PubMed ID: 33113546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.
    Nicoară SD; Ștefănuţ AC; Nascutzy C; Zaharie GC; Toader LE; Drugan TC
    Med Sci Monit; 2016 Apr; 22():1192-209. PubMed ID: 27062023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.